Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

Tilotta, Giovanna; Pistone, Giuseppe; Caruso, Paolo; Gurreri, Rosario; Castelli, E.; Curiale, Salvatrice; Caputo, Valentina; Bongiorno, Maria Rita

doi:10.1111/ijd.15352

Cited by 7 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, adherence largely improved after further discussion with a dermatology provider [15]. Other studies made similar observations: frequent communication with providers to address patient concerns and provide more continuity in patient education may improve adherence [3,5,13].…”

Section: Discussionmentioning

confidence: 73%

“…In 2020, an observational study was conducted to assess adherence during the lockdown phase of the COVID-19 pandemic in Italy [ 3 ]. Patients were contacted regularly by their dermatology provider to check in and inquire about adherence.…”

Section: Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…The coronavirus disease 2019 (COVID-19) pandemic raises many challenges for dermatology [1][2][3]. Safety is a principal concern for many patients, particularly those on medications that affect immune function [1,[3][4][5][6][7]. Preventative discontinuation of biologic agents is not recommended; biologics potentially may limit the hyperinflammatory cascade of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

“…Preventative discontinuation of biologic agents is not recommended; biologics potentially may limit the hyperinflammatory cascade of COVID-19. Nevertheless, patients may be fearful and not be fully adherent to anti-inflammatory treatments during the pandemic [1][2][3]5,8]. Even without the pandemic, non-adherence to dermatologic treatment is common and may be exacerbated by COVID-19 concerns [7,9,10].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Treatment Adherence in Dermatology During the COVID-19 Pandemic: A Review

Bridgeman¹,

Perche²,

Feldman³

2023

Cureus

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic raised many challenges for dermatology. Safety is a principal concern for many patients, particularly those on medications that affect the immune system. Understanding how the pandemic affects patients' treatment adherence may be informative for counseling or other interventions to assure that treatment plans are not inappropriately interrupted, or for future pandemics. The purpose of this review was to investigate the extent to which the COVID-19 pandemic affected medication adherence in dermatology. A literature search of PubMed was performed using the search terms: adherence, compliance, dermatology, COVID-19, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), and pandemic. Eleven primary research studies met the inclusion criteria and were included in the review. During the COVID-19 pandemic, non-adherence in dermatology patients was primarily linked to concern about the risk of COVID-19 infection with long-term use of immunomodulatory and immunosuppressive medications. In some cases, non-adherence was associated with feelings of depression, anxiety, or perceived stress. High adherence was attributed to regular and convenient communication between patients and dermatology providers through the effective use of telemedicine and electronic messaging. Frequent communication with providers to address patient concerns and provide continuity of care improved adherence. An integrated virtual approach to patient care facilitated this, particularly through the use of telemedicine. Implementation of routine virtual questionnaires was, to some extent, effective in replacing limited in-person patient-provider interactions during the pandemic. Finally, the added threat of the pandemic presented an additional mental health component to consider for patients, supporting the need for a multidisciplinary approach to patient care.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment Adherence in Dermatology During the COVID-19 Pandemic: A Review

Bridgeman¹,

Perche²,

Feldman³

2023

Cureus

View full text Add to dashboard Cite

show abstract

A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting

Ghoreishi Amin,

Khosravi,

Atefi

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

IntroductionThis systematic review and meta‐analysis aims to investigate the mutual impact of COVID‐19 and psoriasis to inform clinical practice and future research.MethodsWe followed the Preferred Reporting Items for Systematic Reviews and Meta‐analysis protocol for systematic reviews and searched PubMed, Web of Science, Scopus, and Google Scholar until May 1, 2022. Eligibility criteria included full‐text articles in English reporting COVID‐19 treatment outcomes in psoriasis patients. Studies on animals, letters to editors, non‐English studies, and studies with no access to full articles were excluded. Search results were screened and data were extracted by two groups of reviewers with any discrepancies resolved by the senior author. The risk of bias was assessed using ROBINS‐I for nonrandomized studies. The hospitalization rate, Intensive Care Unit (ICU) admission rate, case fatality rate, odds ratios of COVID‐19 infection and hospitalization rate in psoriasis patients were extracted and analyzed using random effects analysis to calculate pooled prevalence and odds ratios, as well as to explore heterogeneity.ResultsWe found 1980 records from four databases and included 20 studies after screening and removing duplicates. These studies evaluated 185,000 psoriasis patients and included eight retrospective cohort studies, one case‐control study, three cross‐sectional studies, and eight case series studies. The impact of the COVID‐19 pandemic on psoriasis treatment and the outcome of COVID‐19 infection in psoriasis patients receiving different forms of treatment were evaluated. The pooled data from included studies showed that the incidence rate of COVID‐19 infection among psoriasis patients was 0.03% (confidence interval [CI]: 0.01–0.06), with a pooled odds ratio of 1.97 (CI: 0.69–5.60) compared to the general population. The hospitalization rate, ICU admission rate, and case fatality rate for psoriasis patients with COVID‐19 were 0.17 (CI: 0.10–0.31), 0.06 (CI: 0.06–0.46), and 0.02 (CI: 0.01–0.04), respectively. Additionally, psoriasis patients receiving systemic nonbiologic therapy had a pooled odds ratio of 2.32 (CI: 1.18–4.57) for hospitalization compared to those using biologic agents.ConclusionStudies have shown that biologic therapy for psoriasis did not increase the risk of hospitalization due to COVID‐19 infection and may have even offered some protection. Treatment adherence was higher in psoriasis patients receiving biologic therapies than those receiving conventional therapies. These findings suggest that psoriasis treatment did not negatively impact COVID‐19 infection and that treatment could be continued on a case‐by‐case basis during the pandemic.

show abstract

Management of Psoriasis Patients with Serious Infectious Diseases

Megna,

Lauletta,

Tommasino

et al. 2024

Adv Ther

View full text Add to dashboard Cite

The management of patients affected by moderate-to-severe psoriasis may be challenging, in particular in patients with serious infectious diseases [tuberculosis (TB), hepatitis B and C, HIV, COVID-19]. Indeed, these infections should be ruled out before starting and during systemic treatment for psoriasis. Currently, four conventional systemic drugs (methotrexate, dimethyl fumarate, acitretin, cyclosporine), four classes of biologics (anti-tumour necrosis factor alpha, anti-interleukin (IL)12/23, anti-IL-17s, and anti-IL-23], and two oral small molecules (apremilast, deucravacitinib) have been licensed for the treatment of moderate-to-severe psoriasis. Each of these drugs is characterized by a unique safety profile which should be considered before starting therapy. Indeed, some comorbidities or risk factors may limit their use. In this context, the aim of this manuscript was to evaluate the management of patients affected by moderate-to-severe psoriasis with serious infectious diseases.

show abstract

Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

Abstract: Adherence to biological therapy in dermatological patients during the COVID-19 pandemic in Western Sicily Dear Editor, COVID-19 has changed all aspects of health care globally, including the way hospital personnel approaches chronic

Cited by 7 publications

References 5 publications

Treatment Adherence in Dermatology During the COVID-19 Pandemic: A Review

Treatment Adherence in Dermatology During the COVID-19 Pandemic: A Review

A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting

Management of Psoriasis Patients with Serious Infectious Diseases

Contact Info

Product

Resources

About